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Alzheimer’s disease (AD) is deﬁned by the concurrence of accumulation of abnormal aggregates composed of two proteins:
Amyloid beta (Aβ) and tau, and of cellular changes including neurite degeneration and loss of neurons and cognitive functions.
Based on their strong association with disease, genetically and pathologically, it is not surprising that there has been a focus
towards developing therapies against the aggregated structures. Unfortunately, current therapies have but mild beneﬁt. With this
in mind we will focus on the relationship of synaptic plasticity with Aβ and tau protein and their role as potential targets for the
development of therapeutic drugs. Finally, we will provide perspectives in developing a multifactorial strategy for AD treatment.
1.Introduction
Amyloid Beta: The Therapeutic Strategy. Alzheimer’s disease
(AD) is histopathologically characterized by extraneuronal
amyloid-betaprotein(Aβ)deposits.Historically,Aβhasbeen
related to cell toxicity and genetic evidence provides the ba-
sis for its proposal as the primary cause of the disease
[1, 2]. Supporting these hypotheses, impairment in Aβ clear-
ance by the central nervous system (CNS) has been reported
in AD patients [3]. In cultured neurons, Aβ was shown to
activate apoptotic pathways, leading to caspase activation,
ultimately contributing to neurodegeneration [4]. It was also
found that Aβ can activate apoptosis signal-regulating kinase
(ASK1) that is required for ROS- and ER-stress-induced JNK
activation and apoptosis, mainly through production of re-
active oxygen species (ROS), but not through endoplasmic-
reticulum-(ER-) mediated stress [2, 5]. Aβ has been found
to modulate redox factor-1 that plays crucial roles in both
cell death signaling pathways and DNA repair by interacting
with transcription factors such as AP-1, NF-kappaB, and
p53 and directly participating in the cleavage of apurinic/
apyrimidinic DNA lesions, therefore aﬀecting both the cell
death signaling pathways and DNA repair [6]. Furthermore,
Aβ was responsible for inducing oxidative stress, predomi-
nantly via mitochondria, which also aﬀected cholesterol ba-
lance [7] and can cause neurotoxicity due to production of
free radicals [8].
The proposed mechanism for Aβ to exert the neurotoxic
eﬀects was the assembly into Aβ plaques and oligomers [9].
This was further nurtured by the ﬁnding of a genetic com-
ponent associated to the hypothesis of Aβ deposition. Muta-
tions in the amyloid precursor protein (APP) that facilitate
its cleavage to generate amyloid peptide and/or mutations
in presenilin-1 (PS-1) or presenilin-2 (PS-2), that promote
amyloid peptide formation and consequently Aβ deposition
have also been reported [10–12]. Although the genetic com-
ponent is documented, we have to mention that far less than
1% of the worldwide AD cases are based on APP or PS2 International Journal of Alzheimer’s Disease
mutations. Indeed, in a systematic genetic study of AD pa-
tients in a Latin American population, PS and APP muta-
tions were absent [13].
Aβ-containingplaqueshavebeenclassiﬁedintosubtypes,
such as senile, diﬀuse, and neuritic [14], with diﬀuse plaques
having little impact on cognitive function, whereas neuritic
plaques are associated with cognitive decline [15]. Therefore,
it was hypothesized that diﬀuse plaques appear during early
preclinical stages of the disease with later appearance of neu-
ritic plaques. However the “peptide to plaque” model re-
mains debated [16]. In recent years, other stages of Aβ aggre-
gation,besideplaques,seemtoplayaroleinthedevelopment
of AD [17]. In this regard it has been shown that the Aβ
aggregation/oligomerization process is playing a central role
in pathogenesis; in other words, one soluble Aβ molecule
(monomer) interacts with other Aβ monomers to form
dimers, oligomers, and polymers, each state of aggregations
forming a potentially pathogenic entity. Indeed, diﬀerent
states of soluble aggregates have been strongly related to
synaptic loss and cognitive impairment [18], a topic that we
will discuss later. From these data, the aggregation state (i.e.,
the diﬀerent oligomers) seems to be related to the disease.
Given that, disaggregation of a plaque will lead to an increase
of Aβ monomers/oligomers and therefore could cause neu-
rotoxicity. Furthermore, inhibiting the formation of aggre-
gates will preserve monomeric or polymeric structures and,
therefore, could cause neurotoxicity. Overall, the perceived
strength of the amyloid cascade hypothesis is reﬂected in the
scientiﬁc literature, which is voluminous and dominated by
experimental studies that adhere to the following statement:
Aβ accumulates in the AD brain, consequently leading to
neurodegeneration [19]. Although spatial distribution of
increased levels of Aβ is related to AD pathology [20]a n d
some degree of correlation with neuronal loss has been re-
ported [21], no strong clinical correlation between plaque
deposition and the degree of cognitive decline during AD
has been found [22]. It is therefore in question whether the
Aβ plaque is responsible for all the damage seen during the
process of neurodegeneration or not.
An Alternative Point of View. We have suggested that Aβ de-
position as plaques could represent the eﬀect rather than the
cause of AD [23, 24]. Aβ aggregation may not be a harbinger
of death, but rather a protective response to neuronal insult
[25]. And, perhaps most contrary to current thinking, due
to the fact that there is a negative correlation between Aβ
deposition and oxidative damage [26], it has been pro-
posed that diﬀuse amyloid plaques may be a compensatory
response aimed at reducing oxidative stress [27–30]. If this
hypothesis is correct, it means that Aβ deposits are simply a
compensatory response, explaining the failure of therapeutic
approaches simply directed to removal of Aβ plaques [31].
2. Aβ: The Therapeutic Target
Presently Aβ is one of the main therapeutic targets. In fact,
immunization with Aβ was successful at removing Aβ from
the brain. Imaging studies in AD patients showed that im-
munization with Aβ decreased amyloid plaques in the
brain; however, this had no eﬀect on cognition [32]. In
mouse models, immunization has cleared small deposits and
diﬀuses Aβ surrounding ﬁbrillar cores [33]. But beyond
removing Aβ, immunization has failed to clearly improve
cognition in patients [34]. Active vaccination with Aβ in pa-
tients with mild-to-moderate AD in a phase II trial showed
CNS inﬂammatory response [35], that was blamed for the
failure. However, the inﬂammatory response has not been
deﬁnitively proven to be the cause for the failure. Despite
this outcome, new vaccines are presently in trial: Eli Lilly’s
solanezumab and Janssen and Pﬁzer’s bapineuzumab (orig-
inally developed by the Dublin-based company Elan), are
using monoclonal antibodies that work with the immune
system, binding to amyloid-β and helping to clear accu-
mulated amyloid-β peptides in the brain. Both are being
tested in phase III trials on thousands of participants with
mild-to-moderate Alzheimer’s disease [36]. Following the
hypothesis of preventing aggregates, β-secretase and γ-
secretase inhibitors have also been used therapeutically, but
with mixed results due to inhibition of other vital pathways,
for example, the Notch pathway [37]. Although the main
goal is to block the production of Aβ [37], γ-secretase
inhibitors also block the proteolytic processing and function
ofNotch,whichisessentialforbrainmorphogenesis,making
γ-secretase a worthwhile but diﬃcult target for intervention
[38]. In sum, the therapeutic outcome of current Aβ-related
trials is rather discouraging. While there are without a doubt
multiple factors that could explain a negative outcome of
these trials, the above hypothesis raises the possibility that
Aβ plaques are not a viable primary therapeutic target.
Overall, there is little debate about Aβ being involved in
AD pathology, but a strong debate about whether it is an
appropriate therapeutic target.
3. Tau Protein:The Therapeutic Approach
Tau is an axonal protein that regulates microtubule stabili-
ty [39]. According to current AD hypotheses, (a) tau be-
comesabnormallyphosphorylated,(b)dissociatesfrommic-
rotubules and, (c) aggregates into neuroﬁbrillary tangles
(NFTs) [40, 41]. Tau has at least 45 phosphorylation sites,
most of them are located in the proline-rich region (P-re-
gion) (residues 172–251) and the C-terminal tail region (C-
region) (residues 368–441) [42]. Tau phosphorylation at
both of these regions aﬀects its capacity to interact with
microtubules [43]. In terms of AD development, the phos-
phorylation sites located in the C-terminal region seem to
playaninterestingrole.PhosphorylationatSer262selectively
impairs binding of tau to microtubules [44]. Phosphory-
lation at Ser202 enhances tau polymerization; phosphory-
lation at the two neighbouring sites Ser202-Thr205 makes
ﬁlament formation more sensitive to small changes in tau
concentration [45]. Taking these data together, it seems that
multiple phosphorylation events of tau, rather than just sin-
gular phosphorylation, play a crucial role during AD-related
tau pathology [46, 47].International Journal of Alzheimer’s Disease 3
The abnormal phosphorylation of tau during AD is
either related to an increase in kinase activity (glycogen
synthase kinase 3β, cyclin-dependent kinase-5, p42/44 MAP
kinase, p38 MAPK, stress-activated protein kinases, mitotic
protein kinases) and/or a decrease in phosphatase activity
(protein phosphatases 1, 2a, 2b) [48–52]. Certainly one
kinase known to be of importance to tau phosphorylation
is GSK3β [53]. In terms of phosphatase deregulation, it has
been shown that protein phosphatases PP1, PP2A, PP2B,
and PP5 dephosphorylate tau in vitro at sites Ser199, Ser202,
Thr205, Thr212, Ser214, Ser235, Ser262, Ser396, Ser404, and
Ser409 [54]. Of all phosphatases, PP2A was found to be the
strongest tau-related phosphatase [54].
4.TherapeuticStrategy
Tau phosphorylation is established as a major factor during
AD with a therapeutic focus on its kinases and phosphatases
[55, 56] .R e c e n t l y ,i tw a sr e p o r t e dt h a ts o d i u ms e l e n a t e
w a sa b l et or e d u c et a up h o s p h o r y l a t i o nb ys t a b i l i z i n g
PP2A, therefore, mitigating tau pathology in transgenic AD
models [57]. Targeting PP2B, several neuroleptics (such as
chlorpromazine, triﬂuoperazine, and clozapine) have also
been suggested for AD treatment [58]. In an approach,
parallel to prevent Aβ plaque formation, drugs that prevent
tau aggregation have also been developed [59, 60]. At the
end, the answer is quite the same: no proven success has yet
emerged from these approaches.
4.1. Synaptic Plasticity: The Link
4.1.1. Synaptic Plasticity and Kinases. Synaptic plasticity has
been proposed to play a central role in brain capacity to in-
corporate transient experiences into persistent memory tra-
ces. Synaptic transmission can be enhanced (long-term po-
tentiation, LTP) or depressed (long-term depression, LTD)
by activity, and these changes can range from seconds to
hours and days [61, 62]. Importantly, the aﬀected intracel-
lular pathways leading to LTP or LTD activation involve se-
veral kinases, such as GSK3β, SRC family tyrosine kinases,
protein kinase A, protein kinase C, and, in particular, Ca2+/
calmodulin-dependent protein kinase II [63, 64], which are
knowntoplayaroleinAD.Giventheimportanceofsynaptic
plasticity, it is not surprising that these phenomena could be
aﬀected during neurodegeneration and AD [65]. Presently,
there is growing evidence that Aβ and tau are involved in
synaptic dysfunction [66, 67]. Reports had placed Aβ close
to synaptic terminals [68]. Indeed, Aβ was found to enhance
N-methyl-D-aspartate (NMDA) receptor function by direct
interaction [69]. Aβ was also found responsible for changes
in presynaptic mechanism at the CA1–CA3 synapse of pyra-
midal neurons in the hippocampus [70] and for functional
deﬁcits in the mossy ﬁbre pathway [71]. Furthermore, Aβ
leads to decreased mitochondria in dendrites that resulted in
the reduction in the number of spines or synapses [72, 73]
and has been related to neuritic degeneration [74]. In the
context of synaptic plasticity, Aβ leads to impairment of
LTP [75] and facilitates LTD [76, 77]. Of note, Aβ has been
suggested to exacerbate synaptic mitochondrial alterations
including increased oxidative stress, decreased respiration,
and compromised calcium handling capacity [78], all of
them having an impact on synaptic plasticity. Overall, there
is growing evidence showing that Aβ is related to changes in
synaptic function.
4.1.2. Phosphorylation as the Link. T h ec r i t i c a lq u e s t i o nt o
raise at this point is how Aβ and tau are interconnected dur-
ing the disease. Although the relationship between these two
proteins remains vague, data has lent support to the hypo-
thesis that phosphorylation of tau protein could be the key
linking mechanism. Ten years ago it was found that Aβ ﬁbrils
accelerate the formation of abnormally phosphorylated neu-
roﬁbrillary tangles (NFTs) in a tau transgenic mouse [79].
The following years, it was reported that Aβ could induce tau
phosphorylation and toxicity in cultured septal cholinergic
neurons [80]. More recently, it has been shown that Aβ
oligomers cause abnormal tau phosphorylation and mor-
phology changes of spines by missorting of endogenous tau
into dendrites [81]. Finally, natural Aβ isolated from AD
brains is suﬃcient to induce AD-type tau phosphorylation
and, consequently, neuritic dystrophy [74]. Concerning
synaptic plasticity, it has been found that the absence of tau
protein inhibits the impairment of LTP and neurotoxicity
caused by Aβ [82] and targeting tau by immunotherapy
prevents cognitive decline in a tangle mouse model [83].
Additionally, recent data show that tau protein has a den-
driticfunctionintargetingtheSrckinaseFyntopostsynaptic
NMDA receptors [84]. Summarizing these data, it appears
thatsynapticfailureandneurotoxicityinducedbyAβ require
tauphosphorylation.Notsurprisingly,eliminationoftauhas
been suggested as a therapeutic target in order to ameliorate
disease progression [85]. However, neuronal alterations that
underlie symptoms of AD are not exclusively due to a direct
toxic eﬀect of Aβ [24]. Furthermore, we do not know the
molecular mechanisms underlying the complex changes of
synaptic plasticity during AD. Just recently, we have found
that tau protein has a physiological function at the synaptic
terminal that is regulated by tau phosphorylation (unpub-
lished data). Therefore, simply getting rid of tau protein as
somehavesuggestedcouldadverselyaﬀecttheequilibriumof
diﬀerent forms of synaptic plasticity. The question remains:
issynapticplasticitythelinkbetweenAβ andtau?Clearly,the
p o t e n c yt ol o o ka tA Df r o mas y n a p t i cp e r s p e c t i v ei st h a ti t
integrates Aβ and tau in a functional concept.
5. Conclusion andPerspectives
PathogenesisofADcomprisesneurodegenerationinthehip-
pocampal area of brain that is critically involved in learning
and memory. Presently, synaptic plasticity (LTP and LTD),
the process by which synapses modulate their connections
with other neurons, seems to be playing an important role
in response to injury and disease. But more importantly,
emerging evidence suggests that synaptic dysfunction beside
neuronal death is leading to cognitive failure associated with















Figure 1: The role of GSK3β and Fyn during AD-related neurodegeneration and memory formation, along with NMDA receptor, makes
them important therapeutic targets (red square). Impairment of hippocampal LTP by Aβ is through direct interaction with NMDA receptor.
Calcium (Ca2+) enters via NMDA receptors and this leads to activation of protein phosphatase 1 (PP1), a key enzyme in synaptically
inducedLTD.PP1candephosphorylateGSK3β thatdetermineswhetherNMDAreceptoractivationinducesLTDorinhibitsLTD.Aβ leadsto
decreased mitochondria and oxidative injury that promotes the release of cytochrome C (Cyt C) that may activate caspase-9 and caspase-3,
which can cleave Akt, resulting in GSK3β activation. GSK3β under the control of Akt and PP1, is a critical determinant of the direction of
NMDA receptor-dependent plasticity. The active GSK3β isoforms critically contribute to neurodegeneration by hyperphosphorylation of
tau which deregulates Fyn activity and consequently aﬀects NMDA receptor response.
a loss of synaptic plasticity. In this regard, a growing amount
of data is showing that Aβ and tau protein are both necessary
tocausechangesin synaptic plasticity. However,thequestion
remains: should either Aβ or tau be the therapeutic targets?
The concept that aggregation of Aβ and tau is deleterious
to cells and amenable to therapeutic molecules may be too
simplistic.Instead,upstreamanddownstreamtargetshaveto
emerge as therapeutic options. In this context, synaptic plas-
ticity modulators could be an interesting target. The most
important aspect of this approach is that synaptic plasticity
linksAβandtautothesynapticterminal.Inthisregard,some
moleculeshavealreadybeentested.Memantine,forexample,
is a partial antagonist of NMDA-receptor function, approved
for moderate-to-severe Alzheimer’s disease (AD) treatment
within the USA and Europe (under the brand name
Namenda (Forest), Axura and Akatinol (Merz), and Ebixa
and Abixa (Lundbeck)), has some promise [86, 87]. Meman-
tine, in its current therapeutic form, only slows down the
neuronal degeneration process, but does not improve cog-
nitive function [88]. However, Memantine might be bene-
ﬁcial to modulate the NMDA-receptor response in earlier
stages of AD, where synaptic plasticity rather than neurotox-
icity is playing a role. Furthermore, another target for thera-
peuticinterventionwouldbeFynkinase,amemberoftheSrc
kinase family, which is intricately involved with potentiating
NMDA-receptor-dependent transmission [89]. Fyn kinase
is receptive to changes in intracellular tau and extracel-
lular Aβ at the synaptic terminal [84, 90]. Therefore, drugs
that directly regulate Fyn activity might be beneﬁcial. Like
Fyn,thereareothertargetscriticallyinvolvedduringsynaptic
plasticity and AD, as previously mentioned. One such target
is GSK3β, which is necessary for the induction of synaptic
LTD, while at the same time inhibits LTP [91].
In summary, it appears that the balance in synaptic
plasticity during AD is tipped toward the induction of LTD.
Hence, drugs that enhance LTP in combination with drugs
that reduce induction of LTD might be of great value to treat
AD.Thistherapeuticapproach(i.e.,simultaneouslytargeting
critical check points for synaptic plasticity) will hopefully
improve memory formation during AD (Figure 1). In sum,
it is becoming all the clearer that approaches that focus on
removing the pathological manifestations of AD might miss
the intended outcome. Therefore, working with the biology
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